Urgent Need for Early Detection in Drug Overdose Cases Highlighted in New Podcast
Episode 49 of QuidelOrtho Science Bytes explores substance use trends, the limits of Narcan, and the evolving challenges facing emergency departments
SAN DIEGO, July 24, 2025 /PRNewswire/ -- In emergency care settings, every second counts. Early drug detection not only improves clinical decision-making, it can be the difference between life and death. But with the rise of counterfeit medications and drug combinations that are more potent and less predictable, emergency departments must adapt faster than ever.
QuidelOrtho Science Bytes Episode 49 "How Urgent Diagnostic Testing Can Help Prevent Drug Overdose Deaths," addresses the escalating complexities of substance use detection and care in emergency departments across the country. The episode features Vonda McAllister, Director of Global Product Management at QuidelOrtho, whose deep experience in diagnostics and toxicology provides critical perspective on the clinical and societal impacts of today's most dangerous drug trends.
Subscribe to QuidelOrtho Science Bytes
Episode Highlights:
- How rapid diagnostic testing is saving lives
- Understanding the unpredictable nature of polydrug overdoses
- The increasing prevalence of potent synthetic drugs like fentanyl, xylazine ("tranq"), and nitazines
- The limitations of Narcan (naloxone) and the rising need for repeated doses due to powerful opioid analogs
- California's "Tyler's Law," which mandates fentanyl testing in suspected overdose cases
Key Quotes:
Vonda McCallister, Director of Global Product Management, QuidelOrtho
"As overdose presentations become more complex, continuous monitoring, comprehensive toxicology screening and clinical vigilance are essential tools in the fight against this crisis."
About QuidelOrtho Science Bytes
Science Bytes is a monthly podcast that delivers diagnostic insights and innovation updates from QuidelOrtho, helping healthcare providers stay informed and prepared. Episode 49 is now available on all major podcast platforms.
For more information and to listen to the full episode, visit www.quidelortho.com/sciencebytes.
About QuidelOrtho Corporation
QuidelOrtho Corporation (Nasdaq: QDEL) is a global provider of innovative diagnostic testing solutions. From infectious diseases to cardiac biomarkers to women's health, QuidelOrtho transforms the power of diagnostics into a healthier future through science, innovation, and accessibility. Learn more at www.quidelortho.com.
Source: QuidelOrtho Corporation
Investor Contact: Juliet Cunningham Vice President, Investor Relations
| Media Contact: D. Nikki Wheeler Senior Director, Corporate Communications
|
View original content to download multimedia:https://www.prnewswire.com/news-releases/urgent-need-for-early-detection-in-drug-overdose-cases-highlighted-in-new-podcast-302512078.html
SOURCE QuidelOrtho Corporation
Übrigens: US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.
Nachrichten zu Quidel Corp.
Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.
Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv
Analysen zu Quidel Corp.
Datum | Rating | Analyst | |
---|---|---|---|
22.01.2018 | Quidel Overweight | Barclays Capital | |
18.07.2017 | Quidel Buy | Canaccord Adams | |
25.04.2017 | Quidel Hold | Canaccord Adams | |
08.01.2016 | Quidel Buy | Canaccord Adams | |
02.09.2015 | Quidel Overweight | Barclays Capital |
Datum | Rating | Analyst | |
---|---|---|---|
22.01.2018 | Quidel Overweight | Barclays Capital | |
18.07.2017 | Quidel Buy | Canaccord Adams | |
08.01.2016 | Quidel Buy | Canaccord Adams | |
02.09.2015 | Quidel Overweight | Barclays Capital | |
04.01.2011 | Quidel outperform | Wedbush Morgan Securities Inc. |
Datum | Rating | Analyst | |
---|---|---|---|
25.04.2017 | Quidel Hold | Canaccord Adams | |
03.03.2011 | Quidel neutral | Wedbush Morgan Securities Inc. | |
30.09.2009 | Quidel market perform | William Blair |
Datum | Rating | Analyst | |
---|---|---|---|
29.08.2006 | Update Quidel Corp.: Strong Sell | Matrix Research |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Quidel Corp. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen